{"version":"1.0","provider_name":"Brakke Consulting\u306e\u30a6\u30a7\u30d6\u30b5\u30a4\u30c8","provider_url":"https:\/\/brakkeconsulting.com\/ja","title":"News from Brakke Consulting","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"u41VJ0z4GW\"><a href=\"https:\/\/brakkeconsulting.com\/ja\/animal-health-news-notes-for-december-18-2020\/\">2020 \u5e74 12 \u6708 18 \u65e5\u306e\u52d5\u7269\u306e\u5065\u5eb7\u306b\u95a2\u3059\u308b\u30cb\u30e5\u30fc\u30b9\u3068\u30ce\u30fc\u30c8<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/brakkeconsulting.com\/ja\/animal-health-news-notes-for-december-18-2020\/embed\/#?secret=u41VJ0z4GW\" width=\"600\" height=\"338\" title=\"&#8220;Animal Health News &#038; Notes for December 18, 2020&#8221; &#8212; Brakke Consulting Website\" data-secret=\"u41VJ0z4GW\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/brakkeconsulting.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>","description":"*********************************** Brakke Consulting&#8217;s Animal Health News &amp; Notes for December 18, 2020 Copyright \u00a9 Brakke Consulting Editor: Lynn Fondon DVM MBA ************************************ IN THE NEWS: Earnings News Avivagen Other News APC Microbiome Ireland California Pet Pharmacy Companion Animal Health DJO Elanco (KindredBio) Elanco (Tarsus) Farmina Pet Food ImmuCell Impossible Foods Kindred Biosciences Linnaeus LiteCure Mars Nestle Purina PetCare Pets at Home Resilient Biotics Revivicor Tarsus Pharmaceuticals Vaxxinova US Wagmo White Dog Labs Zoetis (Vaxxinova) Zoetis (Solensia) Zomedica ************************************ COMPANY EARNINGS RELEASES Avivagen reported its financial results for the fiscal year ended October 31, 2020. The Company reported revenues of C$1,177,857 ($977,451 in the prior fiscal year) and a comprehensive loss of C$(4,751,287) compared to a comprehensive loss of $(4,836,420) in the prior-year period. (company press release) ************************************ COMPANY NEWS RELEASES Elanco Animal Health announced an agreement with Kindred Biosciences to acquire exclusive global rights to KIND-030, a first-of-its-kind monoclonal antibody being developed for the treatment and prevention of canine parvovirus (CPV). The global license includes an upfront payment of $500,000 and additional milestone payments; sales performance will result in royalties and additional milestone payments for achieving revenue targets. Additionally, as part of the agreement, KindredBio also has a right of last refusal to manufacture certain other Elanco monoclonal antibodies. (company press release) Elanco announced it has expanded its agreement TarsusView Full Post;","thumbnail_url":"https:\/\/brakkeconsulting.com\/wp-content\/uploads\/2020\/12\/Stock-Table-12.18.jpg"}